These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 30684041)
1. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. Pham PA; Dressler C; Eisert L; Nast A; Werner RN Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041 [TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807 [TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Kawalec P; Holko P; Moćko P; Pilc A Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB; Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. Dressler C; Eisert L; Pham PA; Nast A J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1249-1260. PubMed ID: 30735612 [TBL] [Abstract][Full Text] [Related]
7. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis. Montezuma T; Probst LF; Almeida MO Adv Rheumatol; 2024 Mar; 64(1):21. PubMed ID: 38515177 [TBL] [Abstract][Full Text] [Related]
9. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS; Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors. Song GG; Lee YH Int J Clin Pharmacol Ther; 2021 Jul; 59(7):511-518. PubMed ID: 33835018 [TBL] [Abstract][Full Text] [Related]
11. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Singh JA; Guyatt G; Ogdie A; Gladman DD; Deal C; Deodhar A; Dubreuil M; Dunham J; Husni ME; Kenny S; Kwan-Morley J; Lin J; Marchetta P; Mease PJ; Merola JF; Miner J; Ritchlin CT; Siaton B; Smith BJ; Van Voorhees AS; Jonsson AH; Shah AA; Sullivan N; Turgunbaev M; Coates LC; Gottlieb A; Magrey M; Nowell WB; Orbai AM; Reddy SM; Scher JU; Siegel E; Siegel M; Walsh JA; Turner AS; Reston J Arthritis Rheumatol; 2019 Jan; 71(1):5-32. PubMed ID: 30499246 [TBL] [Abstract][Full Text] [Related]
12. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361 [TBL] [Abstract][Full Text] [Related]
13. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis. Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448 [TBL] [Abstract][Full Text] [Related]
14. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD; Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214 [TBL] [Abstract][Full Text] [Related]
15. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis. Mourad A; Gniadecki R J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641 [TBL] [Abstract][Full Text] [Related]
17. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis. Song GG; Lee YH Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450 [TBL] [Abstract][Full Text] [Related]
18. Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study. Ballegaard C; Jørgensen TS; Skougaard M; Strand V; Mease PJ; Kristensen LE; Dreyer L; Gottlieb A; de Wit M; Christensen R; Tarp S Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1206-1217. PubMed ID: 29073353 [TBL] [Abstract][Full Text] [Related]
19. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L; Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]